• No results found

Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion

N/A
N/A
Protected

Academic year: 2020

Share "Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion"

Copied!
6
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Figure 2 Visual acuity in logMAr of eyes treated with grid photocoagulation combined with iVB).Abbreviation: combined with an intravitreal bevacizumab (iVB) for the treatment of recurrent macular edema associated with retinal vein occlusion
Figure 4 recurrence of macular edema after grid photocoagulation combined with intravitreal bevacizumab (iVB) for recurrent macular edema associated with branch retinal vein occlusion

References

Related documents

In this and subsequent papers [ 1 , 20 , 26 ], it is showed that if two messages are not distinguishable in the symbolic model, then their computational interpretations cannot

Any person who has been convicted of the commission of, or attempt to commit, or abetment of, or criminal conspiracy to commit any of the offences punishable

Spatial distribution of the sensible heat flux as shown in figure 4a showed that pixels with higher surface temperature correspond to area with that has the highest values

Tablet quality control tests such as weight variation, hardness, and friability, thickness, and drug release studies in different media were performed on

This analysis was used to investigate the presence of hydrogen bonds and intermolecular interactions in the crystal structure. The Hirshfeld surface analysis 26 was

The proposed algorithm for synchronizing lane changes with SUMO yields a more realistic behavior of other traffic participants, and our extension of lane-change models yields

Similar to the case of association rules [ 1 ], the notions of support and confidence have two purposes: to avoid presenting negligible information to the user, and to cut off

Having demonstrated that these peptides are presented in the context of HLA A*0201, we then tested them in an MHC-I binding assay to confirm their specificity. To this end, Pro-